Research brief / about this project
About Meds Sermorelin
An independent editorial readout of the published GHRH(1-29) record — what it is, and what it is not.
What this site is
Meds Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin (GHRH(1-29)). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — a sourced digest, organized so that each finding sits beside the study that produced it.
What the name means
The word 'meds' in this domain is editorial framing, not a service. This site does not dispense, prescribe, compound, or sell anything, and it is not a pharmacy or a storefront. The name signals the subject — a compound with a real clinical and regulatory history — and the register in which we cover it: a dark, release-note readout of the literature, where the status of the science is stated plainly and dated to its source. Sermorelin's own status is a case in point: a formerly FDA-approved compound, withdrawn for commercial reasons, now compounded — a status often misreported, which is exactly why we state it carefully.
How we handle the evidence
The editorial discipline here is simple: lead with what was measured, attribute it to the study, and mark the gaps as gaps. Where the data is precise — a ~10-12 minute half-life, a 117% IGF-1 rise in a controlled trial — we are precise. Where it is thin — long-term adult anti-aging safety — we say so rather than fill the space. Every quantitative claim on the site resolves to a numbered citation on the references page, and the tolerability caveats are surfaced as their own signal, never buried.
Why a sermorelin-specific digest is worth doing
Sermorelin sits in an awkward gap online: it has a genuine clinical and regulatory history, a characterized mechanism, and real trial data — and it is also wrapped in a layer of anti-aging promotion that frequently misstates both the science and the regulatory status. A focused digest can do one useful thing the noise can't: hold the actual record in one place, with each claim next to its source, the misreported approval history stated correctly, and the honest gaps left visible. That is the whole editorial premise here — the literature, read straight, in a register that flags what it doesn't know.
What we don't do
We don't recommend doses for humans, we don't sell or source any compound, and we don't offer treatment, consultation, or prescriptions. We describe research findings in study-attributed terms. Sermorelin is widely marketed for benefits that outrun the evidence; our role is the opposite of that marketing — to report the record as it stands, including where it runs out.